Mactor ASP 75 Capsule contains a combination of Atorvastatin 10 mg and Aspirin 75 mg, formulated to provide dual therapeutic benefits in cardiovascular risk management. Atorvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C), thereby reducing the risk of atherosclerosis and related cardiovascular events. Aspirin, an antiplatelet agent, irreversibly inhibits cyclooxygenase-1 (COX-1), resulting in decreased thromboxane A2 production and subsequent inhibition of platelet aggregation. This combination is particularly beneficial for patients with a history of coronary artery disease, stroke, or peripheral arterial disease, as it addresses both lipid abnormalities and thrombosis risk. Mactor ASP 75 is indicated for secondary prevention of myocardial infarction, stroke, and other cardiovascular complications in high-risk patients. The capsule should be administered once daily, preferably in the evening, to optimize lipid-lowering effects. Caution is advised in patients with active peptic ulcer disease, bleeding disorders, or hypersensitivity to aspirin or statins. Regular monitoring of liver function tests, lipid profile, and complete blood count is recommended during therapy. Mactor ASP 75 Capsule should be used under medical supervision to ensure safety and efficacy.